You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK)結束特那西普臨床三期試驗
阿思達克 10-10 16:40
和鉑醫藥-B(02142.HK)公布,已決定按照獨立數據監察委員會(IDMC)的建議,結束其於中國的特那西普(HBM9036)臨床三期試驗,不再入組新受試者。 和鉑醫藥指,基於觀察到的療效不足趨勢,IDMC建議公司根據臨床試驗方案終止該試驗。因此,公司將不會對該試驗新增受試者入組,但將繼續依照臨床試驗方案為現有受試者進行隨訪。直至目前為止,試驗過程中並無觀察到任何嚴重安全隱患的信號。 鑒於公司將繼續為該試驗的現有受試者完成隨訪,公司將在餘下試驗採集全部數據的基礎上,進一步評估及決定關於開發特那西普(HBM9036)的未來計劃;及已撥資於特那西普(HBM9036)開發的所得款項於未來十二個月內的用途不會有即時改變,以備餘下試驗完成。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account